Chronic Obstructive Pulmonary Disease, COPD Clinical Trial
Official title:
A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily
The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00108823 -
The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)
|
Phase 3 | |
| Completed |
NCT03064113 -
Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
| Completed |
NCT02442206 -
Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients
|
Phase 4 | |
| Completed |
NCT03095456 -
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
|
Phase 3 | |
| Completed |
NCT02615795 -
Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease
|
N/A | |
| Completed |
NCT02449018 -
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
|
Phase 2 |